Read our latest updates & insights

EMA approves biosimilar pegfilgrastim Pelmeg® for patients undergoing cytotoxic chemotherapy for malignancy, with the exceptions of chronic myeloid leukaemia and myelodysplastic syndromes.

Fuji Pharma and Alvotech announce exclusive partnership agreement for the commercialisation of Alvotech’s biosimilars in Japan. Fuji Pharma will be responsible for the registration and commercialisation of products, while Alvotech will be responsible for development a...

Sandoz receives approval for rituximab biosimilar under two presentations and two brands. The approval includes 500mg/50mL Rixonfya®, 100mg/10 mL Rixonfya®, 500mg/50mL Rixvyda® and 100mg/10mL Rixvyda®. Sandoz is currently prevented from supplying for use, selling, supplying...

China’s National Medical Products Administration accepts Innovent’s application for biosimilar adalimumab. The application seeks approval for the treatment of ankylosing spondylitis, rheumatoid arthritis, and psoriasis.

Coherus discloses newly approved biosimilar Udencya® will be available at a 33% discount to Neulasta®, matching the price point for Mylan’s biosimilar Fulphila®. The product is due to be launched on 3 January 2019.

Biogen and Samsung Bioepis close asset transfer to increase Biogen’s share in Samsung Bioepis to 49.9%. This deal originates from the initial creation of Samsung Bioepis and the partnership between Biogen and Samsung BioLogics, in which Biogen was granted an option to...

AbbVie announces a 6th global deal for biosimilar AmAb, this time with Momenta.  Momenta has obtained a global royalty bearing licence beginning on 20 November 2023 for the US, and in the EU “on approval” (no other dates disclosed). Momenta will be able to launc...

FDA approves Coherus’ biosimilar pegfilgrastim Udencya® for patients receiving myelosuppressive chemotherapy. This is the first US/EU approved biosimilar approved for this indication.

Sandoz announces it will not pursue biosimilar rituximab in the US following requests from the FDA for additional information to complement the BLA.

Sandoz’s biosimilar Zarxio® is included in Express Script’s 2018 National Preferred Formulary.